SynthesisWorld journal of surgical oncology2025
Association of progesterone receptor status with breast cancer prognosis: a meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence.Breast cancer (Tokyo, Japan) · 2026Article
- Higher Levels ofMedical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.
objectiveThis study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.
methodsPubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle-Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.
resultsThirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; p < 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, p < 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, p < 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, p < 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.
conclusionPR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.